Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 9/20 | 0.53 |
| ▸ | XIAP | P98170 | 2/20 | 0.52 |
| ▸ | BIRC3 | Q13489 | 2/20 | 0.52 |
| ▸ | ACE | P12821 | 4/20 | 0.48 |
| ▸ | REN | P00797 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PEPD | P12955 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15093340 | 1.00 | BIRC2 (0.53) | BIRC2XIAPBIRC3ACEREN | |
| SCHEMBL21175408 | 1.00 | BIRC2 (0.53) | BIRC2XIAPBIRC3ACEREN | |
| SCHEMBL15064278 | 1.00 | BIRC2 (0.53) | BIRC2XIAPBIRC3ACEREN | |
| SCHEMBL3507780 | 1.00 | BIRC2 (0.53) | BIRC2XIAPBIRC3ACEREN | |
| SCHEMBL28911875 | 1.00 | BIRC2 (0.53) | BIRC2XIAPBIRC3ACEREN | |
| SCHEMBL15065057 | 1.00 | BIRC2 (0.53) | BIRC2XIAPBIRC3ACEREN | |
| SCHEMBL15064445 | 0.99 | BIRC2 (0.52) | BIRC2XIAPBIRC3ACEREN | |
| SCHEMBL15064444 | 0.99 | BIRC2 (0.52) | BIRC2XIAPBIRC3ACEREN | |
| SCHEMBL28549430 | 0.99 | BIRC2 (0.52) | BIRC2XIAPBIRC3ACEREN | |
| SCHEMBL15064522 | 0.95 | ACE (0.50) | BIRC2XIAPBIRC3ACEREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11963994-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20220211797-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2022-07-07 | — | — | US | disclosed |
| CN-107915728-B | IAP inhibitors | 库里斯公司 | 2021-04-30 | — | — | CN | disclosed |
| US-20190224269-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2019-07-25 | — | — | US | disclosed |
| EP-3133073-B1 | INHIBITORS OF IAP | CURIS INC (US) | 2018-05-02 | — | — | EP | disclosed |
| US-20170136084-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-9586991-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| EP-3133073-A2 | INHIBITORS OF IAP | Curis, Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-2800749-B1 | INHIBITORS OF IAP | CURIS INC (US) | 2016-09-21 | — | — | EP | disclosed |
| US-20160102119-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-9238675-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20140235551-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8716236-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130172264-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170136084-A1 | INHIBITORS OF IAP | BIRC5, XIAP, BIRC3 | BIRC2 5/4885XIAP 2/4885BIRC3 3/4885 |
| US-20190224269-A1 | INHIBITORS OF IAP | BIRC5, XIAP, BIRC3 | BIRC2 5/4885XIAP 2/4885BIRC3 3/4885 |
| US-20130172264-A1 | INHIBITORS OF IAP | BIRC5, XIAP, BIRC3 | BIRC2 5/4885XIAP 2/4885BIRC3 3/4885 |
| US-20140235551-A1 | INHIBITORS OF IAP | BIRC5, XIAP, BIRC3 | BIRC2 5/4885XIAP 2/4885BIRC3 3/4885 |
| US-20160102119-A1 | INHIBITORS OF IAP | BIRC5, XIAP, BIRC3 | BIRC2 5/4885XIAP 2/4885BIRC3 3/4885 |
| US-20220211797-A1 | INHIBITORS OF IAP | BIRC5, XIAP, BIRC3 | BIRC2 5/4885XIAP 2/4885BIRC3 3/4885 |
| US-11963994-B2 | Inhibitors of IAP | BIRC5, XIAP, BIRC3 | BIRC2 5/4885XIAP 2/4885BIRC3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.